U.S. President Donald Trump on Thursday struck deals with obesity drug manufacturers Eli Lilly and Novo Nordisk aimed at improving accessibility by lowering the cost of the medicine.

Speaking inside the Oval Office alongside drug executives at the White House, Trump unveiled landmark agreements with the drug-makers that will cut prices of so-called GLP-1 drugs for Medicare and Medicaid beneficiaries in 2026.

Treatments will be offered directly to consumers at a discount on the website TrumpRx.gov being launched by the Trump administration in January, 2026.

Under the new plan, Medicare will start covering obesity drugs for some patients for the first time in mid-2026. It’s a move that could broaden the market for the medicines and spark more private insurers to cover them.

Certain Med

See Full Page